Many combination therapies, which are often used in the treatment of diseases such as cancer, have failed to secure National Health Service reimbursement in the UK in recent years. This is because the sponsors of different medicines have been reluctant to work together on making the combination therapies cost effective for fear of breaching competition law, the UK’s competition watchdog has said.
UK’s Competition Body Says Pharma Firms Can Work Together On Access To Combination Therapies
The UK’s Competition and Markets Authority will not prioritize the investigation of pharmaceutical companies that enter commercial negotiations with the aim of making combination therapies cost effective, a move that the ABPI says is an “international first”.
More from Pricing Debate
• By
Jonathan Blum, who was principal deputy administrator during the Biden Administration, explained the agency’s approach to setting up the price negotiation program and said changes likely will be implemented by the Trump Administration.
• By
Eli Lilly is seeking an injunction barring a weight loss clinic from dispensing modified versions of its GLP-1 products.
• By
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.
• By
A Republican think tank suggested variations of the Most Favored Nation and international reference policies in Medicare and Medicaid, as well as tariffs and other trade levers to rebalance drug pricing disparities between US countries and abroad.
More from Market Access
• By
Eli Lilly is seeking an injunction barring a weight loss clinic from dispensing modified versions of its GLP-1 products.
• By
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.
• By
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?